Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Antidepressant Suicide Risk Eclipsed By Danger Of No Treatment – NIMH Chief

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA action to emphasize the risks of prescribing antidepressant drugs to children and adolescents would endanger minors with depression and run counter to the evidence emerging from a National Institute of Mental Health study, NIMH Director Insel says.

You may also be interested in...



Pediatric Exclusivity Studies Will Be Included In Labeling, FDA Says

FDA is in the process of developing a policy for including results from studies conducted under the Best Pharmaceuticals for Children Act in labeling, Office of Medical Policy Director Temple says during House hearing on antidepressants.

Anthrax Vaccine Is HHS' First Contract Award Under Project BioShield

VaxGen receives $877.5 mil. contract to supply 75 mil. doses of its recombinant protective antigen anthrax vaccine to the national stockpile within three years. The contract is contingent upon FDA clearing the vaccine for use under emergency conditions.

NIH Alzheimer’s Initiative To Promote Neuroimaging, Identify Biomarkers

Program aimed at speeding Alzheimer’s drug development through neuroimaging and biomarkers is launched by the National Institute on Aging through a five-year, $60 mil. project. Large pharma companies are contributing funds to a multi-site study of 800 subjects.

Topics

UsernamePublicRestriction

Register

PS060670

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel